7월13일 다올투자증권 리서치센터 이지수님이 올려주신 자료를 AI로 편집한 내용 입니다.

① Infliximab (오리지널: Remicade)

Remicade (오리지널): 393.8k units (MOM +8.2% / M/S 48.0%)

Inflectra (셀트리온): 252.4k units (MOM +9.4% / M/S 30.8%)

Avsola (암젠): 89.8k units (MOM +5.2% / M/S 10.9%)

Renflexis (삼성바이오에피스): 84.6k units (MOM +5.9% / M/S 10.3%)

② Rituximab (오리지널: Rituxan)

Truxima (셀트리온): 2,210.9k units (MOM +8.9% / M/S 38.7%)

Ruxience (화이자): 1,836.2k units (MOM +5.5% / M/S 32.2%)

Rituxan (오리지널): 1,358.5k units (MOM +12.5% / M/S 23.8%)

Riabni (암젠): 303.0k units (MOM +7.3% / M/S 5.3%)

③ Trastuzumab (오리지널: Herceptin)

Kanjinti (암젠): 736.1k units (MOM +7.1% / M/S 34.7%)

Trazimera (화이자): 531.7k units (MOM -3.2% / M/S 25.1%)

Ogivri (마일란): 494.8k units (MOM +1.9% / M/S 23.3%)

Herceptin (오리지널): 216.5k units (MOM -1.2% / M/S 10.2%)

Ontruzant (삼성바이오에피스): 76.7k units (MOM +1.2% / M/S 3.6%)

Herzuma (셀트리온): 66.2k units (MOM +41.6% / M/S 3.1%)

④ Bevacizumab (오리지널: Avastin)

Mvasi (암젠): 99.8k units (MOM +5.6% / M/S 52.3%)

Zirabev (화이자): 50.0k units (MOM +6.7% / M/S 26.2%)

Avastin (오리지널): 22.9k units (MOM +14.3% / M/S 12.0%)

Vegzelma (셀트리온): 18.0k units (MOM -6.6% / M/S 9.4%)

⑤ Adalimumab (오리지널: Humira)

Humira CF (오리지널): 117.3k units (MOM +10.1% / M/S 39.1%)

Hadlima (삼성바이오에피스): 49.6k units (MOM +7.9% / M/S 16.5%)

Hyrimoz (산도즈): 41.6k units (MOM +20.2% / M/S 13.9%)

Cyltezo (베링거인겔하임): 30.3k units (MOM +30.2% / M/S 10.1%)

Yuflyma (셀트리온): 24.8k units (MOM +15.8% / M/S 8.3%)

⑥ Ustekinumab (오리지널: Stelara)

Stelara SC (오리지널): 689.9k units (MOM -1.0% / M/S 35.4%)

Yesintek (바이오콘): 612.7k units (MOM +10.1% / M/S 31.4%)

Steqeyma (셀트리온): 276.9k units (MOM +10.1% / M/S 14.2%)

Selarsdi (알보텍): 171.6k units (MOM -2.4% / M/S 8.8%)

Pyzchiva (삼성바이오에피스): 113.5k units (MOM +25.2% / M/S 5.8%)

아래 그래프는 오류가 있는것 같습니다
복사해서 그대로 올린건데 연구원이 실수를 한것 같습니다